Importantly, this finding shows for the first time that arimoclomol is able to rescue the defining pathological hallmark of ALS not only in mouse models of SOD1-ALS [27, 29] but also in a model of non-SOD1 ALS, suggesting that it may have therapeutic potential for ALS more broadly. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.